Eos Capital has acquired a 35% stake in Fabupharm (Pty) Ltd to support its ambitions in the Namibian pharmaceutical market, pending regulatory approval.
Target Company Overview
Eos Capital has announced the acquisition of a 35% stake in Fabupharm (Pty) Ltd, pending approval from the Namibian Competition Commission. This investment aims to bolster Fabupharm's ambitions of establishing a significant presence in both the Namibian and regional pharmaceutical sectors.
Fabupharm, the only pharmaceutical manufacturing facility in Namibia, was founded in 1989 and is situated in Otjiwarongo. The company employs over 70 Namibians and adheres to strict World Health Organization standards required for pharmaceutical production. Fabupharm manufactures a diverse range of products, including paracetamol, antibiotics, vitamin supplements, body lotions, and sunscreen, contributing to an expanding catalogue of locally produced goods.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The pharmaceutical industry in Namibia is poised for growth, with Business Monitor International estimating its value to be around N$3 billion in 2016. Currently, this ma
Similar Deals
Eos Capital → Erongo Medical Group
2025
Eos Capital → Erongo Medical Group (Pty) Ltd
Sheridan Capital Partners → ICANotes
2026
G Square → Serres
2026
St. Cloud Capital → Core Analytics Lab & Radiology
2026
Eos Capital
invested in
Fabupharm (Pty) Ltd
in 2016
in a Other Private Equity deal